<DOC>
	<DOCNO>NCT02253849</DOCNO>
	<brief_summary>Study assess steady-state pharmacokinetics carbamazepine ( CBZ ) 200 mg 100 mg twice daily , depend tolerability , administer alone combination tipranavir/ritonavir ( TPV/r ) single dose ( 500/200 mg ) steady-state ( 500/200 mg twice-daily )</brief_summary>
	<brief_title>Effects TPV/r Pharmacokinetics Carbamazepine Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Healthy male nonpregnant , nonlactating female subject determine result screen Signed write informed consent accordance Good Clinical Practice ( GCP ) local legislation The ability understand sign write informed consent form , prior participation screening procedure must willing comply study requirement Age &gt; 19 &lt; 59 year Weight ≥ 60 kg BMI &gt; 18.5 &lt; 35 kg/m2 Ability maintain adequate contraception applicable Any find medical examination ( include blood pressure , pulse rate , electrocardiogram ) deviate normal clinical relevance AV block include 1° Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic , haematological , oncological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder Relevant history orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Known hypersensitivity TPV , Ritonavir ( RTV ) , carbamazepine antiretroviral drug ( market experimental use part clinical research study ) Known elevate liver enzyme past trial compound Intake drug long halflife ( &gt; 24 hour ) ( &lt; 1 month prior administration trial ) Prescription counter medication ( include vitamin , mineral , herbal supplement antacid ) , dietary supplement 14 day prior study drug administration expect trial ) Participation another trial investigational drug ( &lt; 2 month prior administration expect trial ) Smoker consumption &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day keep tobacco intake constant Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation loss &gt; 400 mL , &lt; 1 month prior administration expect trial Clinically relevant laboratory abnormality Inability comply dietary regimen study centre For female subject : Pregnancy plan become pregnant within 60 day study completion Positive pregnancy test Have use barrier method contraception least 3 month prior participation study Are willing unable use reliable method barrier contraception ( diaphragm spermicidal cream/jelly condoms spermicidal foam ) , 2 month completion/termination trial Chronic use oral contraception hormone replacement contain ethinyl estradiol Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>